Zubina Unjom, MD
Endocrinology, Diabetes & Metabolism · Gurnee, ILNPI 1689027096
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Insulet Corporation at 25.6% of the total. 2025 is the largest year on record at $344, more than ten times the $15 reported in 2021. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in IL, where the typical reported total is $721.
Across 24 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$137
- Corcept Therapeutics$82
- Sanofi-aventis U.S. LLC$55
- Abbott$49
- Xeris Pharmaceuticals, Inc.$45
- Madrigal Pharmaceuticals$42
- plus $125 from 6 others
What the payments were for
- Food & beverage$536100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 7 | $137 |
| Corcept Therapeutics | 3 | $82 |
| Sanofi-aventis U.S. LLC | 2 | $55 |
| Abbott | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Madrigal Pharmaceuticals | 1 | $42 |
| Medtronic | 1 | $26 |
| Novartis | 1 | $26 |
| BETA Bionics, Inc. | 1 | $22 |
| AbbVie | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$536 in reported general payments places this provider in the 45th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 116 | $135,993 |
| OzempicSemaglutide | 74 | $83,881 |
| JardianceEmpagliflozin | 44 | $39,494 |
| MounjaroTirzepatide | 16 | $26,191 |
| Humalog Kwikpen U-100Insulin Lispro | 72 | $25,395 |
| FarxigaDapagliflozin Propanediol | 19 | $20,383 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 116 | $14,228 |
| TradjentaLinagliptin | 18 | $14,029 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $12,262 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 11 | $10,611 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $8,533 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 27 | $8,062 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $6,371 |
| Novolog FlexpenInsulin Aspart | 23 | $3,591 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $2,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $15 | $53,52462 claims |
| Sanofi-aventis U.S. LLCLantus | $55 | $2,57813 claims |
| AbbVieSynthroid | $19 | $2,24927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Gurnee
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
- Daniel SoArlington Heights$283K
- Silvana PannainChicago$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.